Fig. 3: Viral kinetic and pharmacokinetic in ZIKV infected cynomolgus macaques treated with FPV. | Nature Communications

Fig. 3: Viral kinetic and pharmacokinetic in ZIKV infected cynomolgus macaques treated with FPV.

From: Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Fig. 3

a Individual plasma viral loads determined by RT-PCR in all animals; b Median plasma viral load values observed in each treatment group; c, d Viral kinetic parameters (peak and AUC viral load) during the first 7 days of infection. Median value is indicated by horizontal bar. Parameters were compared between groups using the two-tailed non-parametric Mann–Whitney test. e, f Viral kinetic parameters (peak and AUC viral load between 0 and 7 dpi) according to geometric mean FPV plasma trough concentration. Grey: untreated; Purple: 150 mg/kg BID. A Spearman correlation test was performed to assess the association between drug concentration and viral kinetic parameters. Two-tailed p values are indicated. g Heatmaps of the concentrations of IL-1RA, CCL2, and IL-15 measured in plasma ZIKV infected animals. The asterisk indicates a significant difference in the concentration of IL-1RA at 4 d.p.e. between the control group and the FPV group. Parameters were compared between groups using the two-tailed non-parametric Mann–Whitney test. The color scale (in pg.mL−1) is shown at the bottom. Source data are provided as a Source Data file.

Back to article page